GH Research PLC accepted for Promising Targets oral session at ACNP

Rhea-AI Filing Summary

GH Research PLC reports that it has been accepted to the Promising Targets Oral Session at the 64th American College of Neuropsychopharmacology annual meeting. The company will present results from its GH001-TRD-201 clinical trial, which focuses on treatment‑resistant depression, during this scientific congress. The meeting is scheduled for January 12–15, 2026 in Nassau, Bahamas, and the presentation will be delivered by Prof Michael E. Thase. An abstract of the presentation content is provided as an exhibit to this report, giving additional detail on the trial results to the scientific and investment community.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025.

Commission File Number: 001-40530

GH Research PLC

(Exact name of registrant as specified in its charter)

Joshua Dawson House

Dawson Street

Dublin 2

D02 RY95

Ireland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F

GH Research PLC announces acceptance to the Promising Targets Oral Session at the 64^th American College of Neuropsychopharmacology (ACNP) annual meeting (the “Congress”) where it will present results related to its GH001-TRD-201 clinical trial. The Congress is scheduled to take place from January 12-15, 2026, in Nassau, Bahamas.

A copy of the abstract for the presentation to be presented by Prof Michael E. Thase during the Congress is attached hereto as Exhibit 99.1.

1

EXHIBIT INDEX

99.1 Abstract for presentation to be presented by Prof Michael E. Thase with Title: GH001 Improves Illness Severity, Anxiety Symptoms, and Quality of Life in Patients with Treatment-Resistant Depression

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GH Research PLC
Date: November 24, 2025
	By:	/s/ Julie Ryan
	Name:	Julie Ryan
	Title:	Vice President, Finance

3

FAQ

What did GH Research PLC (GHRS) announce in this Form 6-K?

GH Research PLC announced that it has been accepted to the Promising Targets Oral Session at the 64th American College of Neuropsychopharmacology annual meeting, where it will present results from its GH001-TRD-201 clinical trial.

Which clinical trial results will GH Research PLC (GHRS) present?

The company will present results related to its GH001-TRD-201 clinical trial, which is being developed for treatment‑resistant depression.

When and where is the ACNP Congress that GH Research PLC will attend?

The 64th American College of Neuropsychopharmacology annual meeting is scheduled to take place from January 12–15, 2026, in Nassau, Bahamas.

Who will present GH Research PLC’s GH001-TRD-201 data at the ACNP meeting?

The abstract and data related to GH001-TRD-201 will be presented by Prof Michael E. Thase during the Congress.

Where can investors find more detail on the GH001-TRD-201 presentation?

A copy of the abstract for the presentation to be given at the ACNP Congress is attached to the report as Exhibit 99.1.

Who signed the GH Research PLC (GHRS) Form 6-K?

The report was signed on behalf of GH Research PLC by Julie Ryan, who serves as Vice President, Finance.